Clobot Q1 2026: Consolidated Sales Up 65%, Net Loss Narrows Despite Higher Operating Loss

Consolidated sales 8.12 billion KRW (+65.0% YoY)
Consolidated operating loss 2.50 billion KRW (expanded from 1.92 billion)
Consolidated net loss 2.21 billion KRW (narrowed from 2.96 billion, improved financial results)
Separate sales 4.95 billion KRW (+36.0% YoY)
Cash & short-term financial instruments 44.71 billion KRW (slight decrease from 49.21 billion at year-end)
Debt ratio 15.4% (consolidated, improved from 20.8% at year-end)
R&D expenses 0.78 billion KRW (increase from 0.72 billion, continued investment)
No share buyback/cancellation or dividend